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Weight gain, dyslipidemia and altered parameters for
metabolic syndrome on first episode psychotic
patients after six-month follow-up
Ganho de peso, dislipidemia e parâmetros alterados
para síndrome metabólica em pacientes de primeiro
episódio psicótico após seguimento de seis meses
Abst rac t
Objectives: Obesity and metabolic abnormalities are frequent in psychotic patients, including first-episode psychosis. We
evaluated weight and metabolic parameters in first-episode psychotic outpatients from the First Episode Psychosis Program,
Universidade Federal de São Paulo. Method: Weight, height, waist and hip circumferences, glucose and lipid levels were
measured at baseline and after a six-month period. Results: Fifty-seven patients were included and 44 (77.2%) of them finished
the study. Patients had a median age of 26.3 years, 60% were men and 43% had a diagnosis of schizophrenia at the endpoint.
Weight and BMI values increased significantly during the follow-up (p < 0.01). The average weight gain at the follow-up was
10.1% of the baseline weight (SD = 11.9). Only women presented significant waist abnormalities: at the first assessment the
waist mean was 79.12 cm (SD = 10.68) and 6 months later it had increased to 89.65 cm (SD = 11.19, z = -3.182, p = 0.001).
After 6 months, the total cholesterol (p = 0.004), and triglyceride levels (p = 0.016) increased, while HDL-cholesterol levels
decreased (p = 0.025). During the follow-up period one patient (2.3%) developed diabetes mellitus, one (2.3%) presented
altered fasting glucose, 12 (27.2%) patients developed at least two altered parameters for metabolic syndrome and 3 (6.8%)
patients developed metabolic syndrome (p = 0.001). Discussion: The results of this study showed that in a short period of time
individuals under antipsychotic treatment had their weight increased significantly and developed important metabolic abnormalities.
Conclusion: Clinicians should be aware of these risks, choose an antipsychotic that causes less weight gain and should monitor
these patients carefully, and recommend prophylactic measures as diet restriction and physical activities.
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Resumo
Objetivos: Obesidade e alterações metabólicas são freqüentes em pacientes psicóticos, inclusive no primeiro episódio psicótico.
Foram avaliados peso e parâmetros metabólicos em pacientes em tratamento no Programa de Episódio Psicótico da Universi-
dade Federal de São Paulo. Método: Peso, altura, medida de cintura e quadril, glicemia e perfil lipídico foram avaliados no
início do tratamento e após seis meses. Resultados: Cinqüenta e sete pacientes foram incluídos no estudo e 44 (72%)
concluíram o estudo. Os pacientes apresentavam em média 26,3 anos, 60% eram do sexo masculino e, ao final do estudo,
43% apresentavam diagnóstico de esquizofrenia. Houve aumento significativo do peso e índice de massa corporal durante o
estudo (p < 0,01). Em média, o peso aumentou 10,1% do peso inicial (SD = 11,9). Apenas mulheres apresentaram altera-
ções na medida da cintura: no início, a média da cintura era de 79,12 cm (SD = 10,68) e, após seis meses, houve um
aumento para 89,65 cm (SD = 11,19, z = -3,182, p = 0,001). Após seis meses, houve aumento do colesterol total
(p = 0,004) e triglicérides (p = 0,016), e diminuição dos níveis de colesterol HDL (p = 0,025). No período, um paciente
(2,3%) desenvolveu diabetes mellitus, um paciente (2,3%) apresentou glicemia de jejum alterada, 12 (27,2%) desenvolveram
pelo menos dois parâmetros alterados para síndrome metabólica, e 3 (6,8%) apresentaram síndrome metabólica (p = 0,001).
Discussão: Os resultados deste estudo mostram que em um curto período de tempo pacientes em tratamento com antipsicóticos
aumentaram substancialmente o peso e desenvolveram importantes alterações metabólicas. Conclusão: Os clínicos devem
estar atentos a esses riscos, escolher medicações que causem menor ganho de peso, devendo monitorar esses pacientes
cuidadosamente e recomendar medidas profiláticas como restrição dietética e atividade física.
Descritores: Psicose; Tratamento primário; Síndrome X metabólica; Obesidade; Ganho de peso
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Int roduct ion
Antipsychotics had a great impact on psychosis prognosis,
and they are considered essential to the treatment of
schizophrenia and related disorders.
1
 A new generation of
antipsychotics has been developed in the last two decades,
and the clinicians’ concerns about side effects as extrapiramidal
symptoms (EPS) and tardive dyskinesia have now been replaced
with weight gain and metabolic disturbances such as diabetes,
hyperprolactinemia and dyslipidemias.
Patients with schizophrenia were more likely to be overweight
or obese, in comparison to the general population
2
 even before
the advent of the new antipsychotics, but nowadays, it can be
considered one of the main issues in psychosis treatment.
The association between weight gain and some of new
antipsychotics was shown in a meta-analysis.
3
 The weight
gain ranged from 0.04 kg with ziprasidone to 4.45 kg with
clozapine. Olanzapine and clozapine were associated with a
higher weight gain compared to patients taking placebo, who
lost, on average, 0.74 kg in ten weeks.
Abnormalities on glucose metabolism are also more common in
schizophrenic patients with or without treatment when compared
to individuals from general population.
4
 A research based on
National Veterans Health Administration data found that, in a period
of four months, 38,632 schizophrenic patients received
antipsychotic prescriptions, with a percentage of 58.6% of them
taking second generation antipsychotics.
5
 These patients presented
a higher prevalence of diabetes mellitus, particularly individuals
under 40 years old (odds ratio: 1.63, CI 95%: 1.23-2.16).
Metabolic syndrome criteria are hyperinsulinemia, low
glucose tolerance, dyslipidemia, hypertension and obesity, and
this syndrome represents a major r isk of  developing
cardiovascular diseases.
6
 Having even one or two features of
the syndrome associated in one study with increased risk of
mortality from coronary heart disease.
6
The results of an American national multisite prospective
trial of antipsychotic effectiveness in patients with chronic
schizophrenia (CATIE study) showed that 35.8% (n = 441) of
the sample met criteria for metabolic syndrome at baseline.
7
The prevalence of metabolic syndrome increases with age,
8
but it might be a concern also in younger patients with
psychosis as studies with first episode psychotic patients have
shown similar pattern regarding weight gain.
9,10
As most of these studies were conducted in developed
countries, we decided to investigate the incidence of risk factors
for metabolic syndrome in a specialized first-episode psychosis
program in São Paulo, Brazil.
Method
The sample was formed by 57 outpatients from a first-episode
psychosis program (PEP) in São Paulo, Brazil from August
2003 to December 2004. On admission, these individuals
were experiencing their first episode of psychosis and had
undergone no more than 3 months of adequate treatment.
This study received approval from the local ethics committee
and all participants signed informed consent (n. 1232-03).
Completed data for the initial and 6-month assessments were
available for 44 patients, 77.8% of the initial sample. At each
assessment moment, the weight, height, waist and hip
circumferences were measured. Subjects were asked to be
present in a 12-hour-fast state for laboratory analysis (glucose
and lipid levels). Weight was evaluated without shoes, with
the individuals wearing light clothes. Waist was considered at
the level of navel.
11
 The measures were collected by the same
investigator in all assessments.
The metabolic syndrome definition from the National
Cholesterol Education Program (NCEP), 2001, was used,
which comprises three or more of the following symptoms: 1)
high blood pressure, i.e.,  130/85 mmHg (or a history of
hypertension); 2) abdominal obesity i.e., waist circumference
> 102 cm in males and > 88 cm in females; 3) fasting blood
glucose  110 mg/dl (or a history of diabetes mellitus); 4)
fasting HDL cholesterol < 40 mg/dl in males and < 50 mg/dl
in females; 5) fasting triglycerides  150 mg/dl.12
As this is a naturalistic study, the antipsychotic was not
controlled (Table 1). At initial assessment, 26 (59.1%) patients
were taking second generation antipsychotics, mainly
risperidone (n = 22, 50%) and at the second assessment
moment, 34 (81.8%) were on low dose of second-generation
antipsychotic.
Data analysis was performed by SPSS 11.5. Weight, BMI
and waist were tested using Wilcoxon test, which is a (non)
parametric test for continuous data; for categorical data
(cholesterol, triglycerides, fasting glucose, altered parameters
for metabolic syndrome), Marginal Homogeneity Test – MH,
an extension of McNemar test, was used. Mann-Whitney test
was performed to compare age between male and female group.
Resu l t s
The mean age of the sample was 26.3 years old. Women
were significantly older (mean = 32.8, SD = 16.2) than
men (mean = 21.9, SD = 4.8; z = -2.058, p = 0.04). The
mean duration of the illness was 187.9 days (SD = 346.5)
and at the end of the study, 19 (43.2%) patients had a diagnosis
of schizophrenia. Table 2 shows weight, BMI and waist at the
baseline and after a 6 months period, separated by gender. As
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it can be seen, weight and BMI increased significantly during
the follow-up period in both male and female (p < 0.01).
On average, patients gained 10.1% of their initial weight
(SD = 11.9), but only women presented significant waist
abnormalities: at the first assessment the waist mean was 79.12
cm (SD = 10.68) and 6 months later it had increased to 89.65
cm (SD = 11.19, z = -3.182, p = 0.001).
At baseline, 88.1% of the sample had the total cholesterol values
at normal range, but at the end of the study the percentage
decreased to 68.3%, and this difference was statistically significant
(p = 0.004). As shown on Table 3, the number of patients with
low HDL increased from 10 (23.8%) to 21 (51.2%) after the 6-
month period (p = 0.025).  At baseline, no patient had high
triglycerides; six months later 7 (17.5%) patients presented
triglycerides above 201 mg/dl (p = 0.016).
One patient (2.3%) developed diabetes mellitus during the study,
and just  one (2.3%) presented al tered fast ing glucose
(MH = -1.342, p = 0.180).
Although blood pressure was not measured in this study, the
number of patients that met criteria for metabolic syndrome was
investigated at the beginning and at the end of the study. At
baseline, just one patient had metabolic syndrome, but at the
end of the follow-up period, 4 patients (9.1%) met the criteria.
One patient (7.7%) was taking a first generation antipsychotics
(chlorpromazine), and 2 (15.4%) were not taking antipsychotics
at the beginning of study; at the endpoint, the same patient taking
chlorpromazine was taking haloperidol and all the others were
taking second generation antipsychotics.
Thirteen (29.5%) of the patients developed at least two altered
parameters for metabolic syndrome (MH, p = 0.001).Family history
of diabetes was found in 20 (45.5%) patients; 12 (27.3%)
patients had a family history of obesity and 9 (20.5%) patients
had a family history of dyslipidemia. There were no
significant differences regarding family history of diabetes,
obesity and dyslipidemia between those subjects who
developed abnormal parameters with those who did not.
Discuss ion
Weight gain and metabolic abnormalities are side effects
more f requent ly associated to second generat ion
antipsychotics (SGA). Patients presented a significant weight
gain during the study, and this is consistent to the literature.
3
Dyslipidemia is a side effect of antipsychotics, especially
second generation antipsychotics (SGA).
4
 Leitão-Azevedo
et al. found a prevalence of 84.7% of dyslipidemia on a
cross-sectional study of 124 schizophrenic patients.
13
 In
our sample, total cholesterol and triglycerides increased,
and HDL cholesterol decreased after treatment, what can
cause an increase in cardiovascular diseases.
In this sample of first-episode psychosis patients, the
frequency of altered parameters of metabolic syndrome was
29.5% after six months. Twelve patients developed altered
parameters for metabolic syndrome, and three patients
developed metabolic syndrome. Metabolic syndrome
incidence may be underestimated since the blood pressure
was not assessed.
Ryan et al. assessed visceral fat distribution on drug-
naïve first-episode patients with schizophrenia and compared
it to a control group.
14
 They selected 19 patients and 19
controls. Patients had three times more intra-abdominal fat
(IAF) than matched control subjects, although they were
not obese (measured by BMI). Abdominal obesity is a key
component of metabolic syndrome, especially in females.
15
In our study, women presented waist to hip ratio altered,
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and this data is also seen in other studies.
14,16
 In the last
decade, metabolic syndrome prevalence has increased and
according to a recent review on gender differences in metabolic
syndrome, this increase has been steeper in women,
particularly in the young ones,
8
 as we observed in our sample:
we found metabolic syndrome in young women (from 14 to
19 years). A literature review on the clinical effects of the
new antipsychotics in women has recommended the rational
use of sex specific antipsychotic treatment.
17
 However, clinical
trials of the new antipsychotics have been conducted, for the
most part, in male participants,
18
 although there have been
recent reports about sex differences regarding side effects and
subjective tolerability of antipsychotic drugs in psychotic
patients.
19,20
Prevention is still the most important procedure to avoid
weight gain.
21
 Faulkner et al., in a systematic review, evaluated
16 pharmacological and behavioral interventions for weight
management in schizophrenic patients.
22
 The conclusions of
the study were the following: only three studies showed at
least 5% of body weight reduction; pharmacological studies
are restricted because these medications may worsen psychotic
symptoms, and it would be necessary to study more behavioral
interventions. Weight management programs based on
nutritional counseling, physical activity and behavioral
interventions have been developed recently
23,24 
and  when
treating an at-risk patient, physicians need to be vigilant in
monitoring antipsychotic medication.
25
 Collaboration between
the psychiatric and diabetology or endocrinologist teams is
essential to minimize the risk of diabetes and obesity in patients
taking second generation antipsychotics.
26
Limitations of the present study are its relatively small sample
size, lack of a control group and, as it was a naturalistic study,
the treatment was not controlled. Sedentary lifestyle was not
assessed during the study, and we know that this is an important
factor on prevention of cardiovascular and metabolic diseases.
The losses to the follow-up were relatively low (22.8%),
assuming that young patients have more difficulties to comply
with treatment.
27
Conclus ions
The results of this study showed that, in a short period of
time, individuals under antipsychotic had their weight
increased substantially/significantly and developed important
metabolic abnormalities. Health care services should adopt
prophylactic measures in order to prevent weight gain and
metabolic disturbances.
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